(Reuters) – AstraZeneca Plc’s COVID-19 vaccine is effective against Delta and Kappa variants, first identified in India, the company said in a statement on Tuesday, citing a study.
The study by Oxford university investigated the ability of monoclonal antibodies in Sera from recovered people and from vaccinated people to neutralize the Delta and Kappa variants, the statement said.
(Reporting by Aishwarya Nair in Bengaluru; Editing by Arun Koyyur)
